Abstract
Prolonged exposure to ketamine, a NMDA receptor antagonist, results in accelerated neurodegeneration and attenuated weight gain in neonatal rats. Suppression of the NMDA receptors by non-competitive antagonists has resulted in conflicting reports of both increased and decreased expression of BDNF. To examine the effect of prolonged ketamine exposure on BDNF expression, we administered saline or ketamine (20mg/kg) at 90-minute intervals over 9 hours to postnatal day 7 (P7) rat pups. The ketamine-treated rat pups had increased neurodegeneration, BDNF and TrkB cDNA products and protein levels. This increased expression of BDNF may be a response to ketamine-induced injury.
Keywords: Ketamine, neonate, BDNF, TrkB, neurodegeneration, NMDA, anesthesia
Current Drug Safety
Title: Prolonged Exposure to Ketamine Increases Brain Derived Neurotrophic Factor Levels in Developing Rat Brains
Volume: 4 Issue: 1
Author(s): Juan C. Ibla, Hideaki Hayashi, Dusica Bajic and Sulpicio G. Soriano
Affiliation:
Keywords: Ketamine, neonate, BDNF, TrkB, neurodegeneration, NMDA, anesthesia
Abstract: Prolonged exposure to ketamine, a NMDA receptor antagonist, results in accelerated neurodegeneration and attenuated weight gain in neonatal rats. Suppression of the NMDA receptors by non-competitive antagonists has resulted in conflicting reports of both increased and decreased expression of BDNF. To examine the effect of prolonged ketamine exposure on BDNF expression, we administered saline or ketamine (20mg/kg) at 90-minute intervals over 9 hours to postnatal day 7 (P7) rat pups. The ketamine-treated rat pups had increased neurodegeneration, BDNF and TrkB cDNA products and protein levels. This increased expression of BDNF may be a response to ketamine-induced injury.
Export Options
About this article
Cite this article as:
Ibla C. Juan, Hayashi Hideaki, Bajic Dusica and Soriano G. Sulpicio, Prolonged Exposure to Ketamine Increases Brain Derived Neurotrophic Factor Levels in Developing Rat Brains, Current Drug Safety 2009; 4 (1) . https://dx.doi.org/10.2174/157488609787354495
DOI https://dx.doi.org/10.2174/157488609787354495 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Contribution and Value of Biomarkers in Acute Aortic Syndromes
Current Pharmaceutical Biotechnology Beneficial Role of Vitexin and Isovitexin Flavonoids in the Vascular Endothelium and Cardiovascular System
Current Nutraceuticals Relevance of the Vascular Effects of Insulin in the Rationale of its Therapeutical Use
Cardiovascular & Hematological Disorders-Drug Targets A Critical Review of Atypical Antipsychotic Utilization: Comparing Monotherapy with Polypharmacy and Augmentation
Current Medicinal Chemistry Impulsive and Compulsive Behaviors During Dopamine Replacement Treatment in Parkinson’s Disease and Other Disorders
Current Drug Safety Expanding Spectrum of Sodium Potassium Chloride Co-transporters in the Pathophysiology of Diseases
Current Neuropharmacology PPARγ in Angiogenesis and Vascular Development
Current Angiogenesis (Discontinued) Noncardiac Surgery: Evaluating and Minimizing Cardiac Risk
Current Cardiology Reviews Comparing the Efficacy and Safety of Dexmedetomidine/Ketamine with Propofol/Fentanyl for Sedation in Colonoscopy Patients: A Doubleblinded Randomized Clinical Trial
CNS & Neurological Disorders - Drug Targets Routine use of Corticosteroids to Prevent Inflammation Response in Cardiac Surgery
Recent Patents on Cardiovascular Drug Discovery The Intriguing Phospholipases A2 Homologues: Relevant Structural Features on Myotoxicity and Catalytic Inactivity
Protein & Peptide Letters Pathophysiology of Blood-Spinal Cord Barrier in Traumatic Injury and Repair
Current Pharmaceutical Design Subject Index to Volume 4
Current Drug Targets - Cardiovascular & Hematological Disorders Adverse Drug Reactions: Trends in a Tertiary Care Hospital
Current Drug Safety Established and In-trial GPCR Families in Clinical Trials: A Review for Target Selection
Current Drug Targets Neuropathic Pain and Lung Delivery of Nanoparticulate Drugs: An Emerging Novel Therapeutic Strategy
CNS & Neurological Disorders - Drug Targets Peripartum Cardiomyopathy: An Intriguing Challenge. Case Report with Literature Review
Current Cardiology Reviews Serelaxin: New Investigational Treatment in Acute Heart Failure
Cardiovascular & Hematological Agents in Medicinal Chemistry Potential Therapeutic Benefits of Dipyridamole in COVID-19 Patients
Current Pharmaceutical Design Heart Failure in South America
Current Cardiology Reviews